Study of TJ033721 (givastomig) in Subjects with Advanced or Metastatic Solid Tumors
This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.
Solid Tumor|Advanced Cancer|Metastatic Cancer|Gastric Cancer|Gastroesophageal Junction Carcinoma|Esophageal Adenocarcinoma
DRUG: TJ033721 (givastomig)|DRUG: TJ033721 (givastomig) , nivolumab, chemotherapy
Dose-limiting toxicities (DLTs), 28 days|Incidence and severity of AEs, The CTCAE criteria will be used to assess adverse events on this trial., Up to 100 days post last dose|Maximum tolerated or administered dose (MTD, MAD), Based on DLT definitions, 28 Days
Pharmacokinetic (PK) Parameters: AUC∞, Area under the curve from time zero extrapolated to infinity (AUC∞), Up to 100 days post last dose|Pharmacokinetic (PK) Parameters: AUCt, AUC from time zero to the time of the last quantifiable concentration (AUC0-t), up to 100 days post last dose|Pharmacokinetic (PK) Parameters: Cmax, Maximum observed concentration, up to 100 days post last dose|Pharmacokinetic Parameters: Tmax, Time of peak concentration (Tmax), up to 100 days post last dose|Pharmacokinetic Parameters: T1/2, Investigational Product (IP) half-life (T1/2), up to 100 days post last dose
This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.